Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Upcoming IPO
Biofrontera (BFRI)
Marpai (MRAI)
Cingulate, Inc. (CING)
Stronghold Digital Mining, Inc. (SDIG)
Enfusion, Inc. (ENFN)
Portillos Inc. (PTLO)
Winc, Inc. (BEV)
The Vita Coco Company, Inc. (COCO)
P10, Inc. (PX)
Ventyx Biosciences, Inc. (VTYX)
Winc, Inc. (WBEV)
Runway Growth Finance Corp (RWAY)
Aris Water Solutions, Inc. (ARIS)
Minerva Surgical, Inc (UTRS)
Xilio Therapeutics, Inc. (XLO)
Informatica Inc. (INFA)
Arteris, Inc. (AIP)
Priced IPO
Mink Therapeutics, Inc. (INKT)
Paragon 28, Inc. (FNA)
Ihs Holding Limited (IHS)
Gitlab Inc. (GTLB)
Lucid Diagnostics, Inc. (LUCD)
Healthcare Triangle (HCTI)
AvidXchange (AVDX)
Cognition Therapeutics, Inc. (CGTX)
Isoplexis Corporation (ISO)
Pyxis Oncology, Inc. (PYXS)
Life Time Group Holdings, Inc. (LTH)
Theseus Pharmaceuticals, Inc. (THRX)
Tricon Residential (TCN)
Volcon (VLCN)
Nuvei (NVEI)
Tdcx, Inc. (TDCX)
First Watch Restaurant Group, Inc. (FWRG)
Exscientia Limited (EXAI)
Warby Parker (WRBY)
Olaplex Holdings Inc. (OLPX)
More companies

Immuneering Corporation (IMRX)

Sector - Healthcare

Price chart

+60.6%
Return from IPO

Company News

IPO Profile

About company

Company Logo
They are a biopharmaceutical company with an emerging pipeline focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying their deep knowledge of translational bioinformatics to every stage of the drug development process. They have more than a decade of experience in translational bioinformatics and generating insights into drug mechanisms of action and patient treatment responses. Building on this experience, they developed a disease-agnostic platform that enables them to utilize human data, novel biology and chemistry, and translational planning to create and advance their wholly owned pipeline. Their current development programs in oncology are focused on providing treatments for patients with solid tumors caused by mutations of the MAPK pathway and other oncologic signaling pathways. Their lead product candidate, IMM-1-104, is designed to be a highly selective dual-MEK inhibitor that further disrupts KSR for the treatment of advanced solid tumors in patients harboring RAS mutant tumors. They plan to submit an IND for IMM-1-104 to the FDA in the first quarter of 2022. In addition, they anticipate filing at least two additional INDs for their other oncology programs, one in each of 2023 and 2024.
Industry
Pharmaceutical Preparations
CEO CFO
Benjamin J. Zeskind Biren Amin
Employees Founded
34 2008

Contacts

Address: 245 Main Street, Second Floor Cambridge, Massachusetts 02142

Telephone: (617) 500-8080

Web page: http://immuneering.com

IPO information

First Trade Date 7/30/2021
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Shares & Volumes

Shares Initial (MM) 7
Shares Revised (MM) 7.5
Expected offer amount (MM) $105
Realized offer amount(MM) $112.5

Financial Data (last reporting year)

Market Cap (MM) $358.35
Revenues (MM) $2.58
Net Income (Loss) (MM) $-20.07

Voting

What do you think will happen with the IMRX share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: Morgan Stanley

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
Underwriters
Morgan Stanley/ Jefferies/ Cowen/ Guggenheim Securities
CO-Managers
-

Sector: Healthcare

Tweets about $IMRX

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats